Amgen Inc. reported on Tuesday that its total revenue in the fourth quarter of fiscal 2024 stood at $9.1 billion, increasing 11% viewed annually. At the same time, operating income (GAAP) increased to $2.3 billion from $1.3 billion in the same quarter of 2023, rising 76%. Diluted earnings per share (EPS) decreased 18% in the fourth quarter and came at $1.16.
For the full fiscal 2024, revenue grew 19%, reaching $33.4 billion, while operating income (GAAP) fell 8% to $7.2 billion compared to the year prior. Diluted earnings per share for 2024 decreased by 39% and landed at $7.56.
"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," CEO Robert Bradway said.
The company's stock dropped 2.26% at 4:33 pm ET in the after-hours trade after the report's release selling for $289.02 apiece.
